ZBIO Covered Call Strategy
ZBIO (Zenas BioPharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
ZBIO (Zenas BioPharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.15B, a beta of -0.69 versus the broader market, a 52-week range of 8.91-44.6, average daily share volume of 719K, a public-listing history dating back to 2024, approximately 130 full-time employees. These structural characteristics shape how ZBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.69 indicates ZBIO has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a covered call on ZBIO?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current ZBIO snapshot
As of June 30, 2026, spot at $25.46, ATM IV 93.50%, IV rank 19.51%, expected move 26.81%. The covered call on ZBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this covered call structure on ZBIO specifically: ZBIO IV at 93.50% is on the cheap side of its 1-year range, which means a premium-selling ZBIO covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 26.81% (roughly $6.82 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ZBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on ZBIO should anchor to the underlying notional of $25.46 per share and to the trader's directional view on ZBIO stock.
ZBIO covered call setup
The ZBIO covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ZBIO near $25.46, the first option leg uses a $26.73 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ZBIO chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ZBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $25.46 | long |
| Sell 1 | Call | $26.73 | N/A |
ZBIO covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
ZBIO covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on ZBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on ZBIO
Covered calls on ZBIO are an income strategy run on existing ZBIO stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
ZBIO thesis for this covered call
The market-implied 1-standard-deviation range for ZBIO extends from approximately $18.64 on the downside to $32.28 on the upside. A ZBIO covered call collects premium on an existing long ZBIO position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether ZBIO will breach that level within the expiration window. Current ZBIO IV rank near 19.51% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ZBIO at 93.50%. As a Healthcare name, ZBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ZBIO-specific events.
ZBIO covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ZBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ZBIO alongside the broader basket even when ZBIO-specific fundamentals are unchanged. Short-premium structures like a covered call on ZBIO carry tail risk when realized volatility exceeds the implied move; review historical ZBIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current ZBIO chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on ZBIO?
- A covered call on ZBIO is the covered call strategy applied to ZBIO (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With ZBIO stock trading near $25.46, the strikes shown on this page are snapped to the nearest listed ZBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ZBIO covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the ZBIO covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 93.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ZBIO covered call?
- The breakeven for the ZBIO covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ZBIO market-implied 1-standard-deviation expected move is approximately 26.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on ZBIO?
- Covered calls on ZBIO are an income strategy run on existing ZBIO stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current ZBIO implied volatility affect this covered call?
- ZBIO ATM IV is at 93.50% with IV rank near 19.51%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.